Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun 1;32(6):1537-1538.
doi: 10.1681/ASN.2021030334. Epub 2021 Apr 13.

Authors' Reply

Steven Fishbane  1 , Mohamed A El-Shahawy  2 , Bui Pham Van  3 , Dustin J Little  4
Affiliations
Comment

Authors' Reply

Steven Fishbane et al. J Am Soc Nephrol. .
No abstract available

Keywords: anemia; chronic kidney disease; erythropoietin.

PubMed Disclaimer

Comment on

References

    1. Eleftheriadis T, Pissas G, Liakopoulos V, Stefanidis I: On the increased event rate of urinary tract infection and pneumonia in chronic kidney disease patients treated with roxadustat for anemia. J Am Soc Nephrol 32: 1537, 2021. - PMC - PubMed
    1. Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, et al. .: Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized Phase 3 study. J Am Soc Nephrol 32: 737–755, 2021. - PMC - PubMed
    1. Eleftheriadis T, Pissas G, Mavropoulos A, Nikolaou E, Filippidis G, Liakopoulos V, et al. .: In mixed lymphocyte reaction, the hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat suppresses cellular and humoral alloimmunity. Arch Immunol Ther Exp (Warsz) 68: 31, 2020. - PubMed
    1. Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, et al. .: Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for treatment of anemia in chronic kidney disease: A placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients. J Clin Pharmacol 60: 1432–1440, 2020. - PMC - PubMed
    1. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. .: Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A Phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67: 912–924, 2016. - PubMed

LinkOut - more resources